SAREPTA THERAPEUTICS ($SRPT) posted quarterly earnings results on Wednesday, August 6th. The company reported earnings of $2.02 per share, beating estimates of $0.75 by $1.27. The company also reported revenue of $611,090,000, beating estimates of $540,582,201 by $70,507,799.
You can see Quiver Quantitative's $SRPT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SAREPTA THERAPEUTICS Insider Trading Activity
SAREPTA THERAPEUTICS insiders have traded $SRPT stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SRPT stock by insiders over the last 6 months:
- CLAUDE NICAISE sold 2,491 shares for an estimated $248,203
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SAREPTA THERAPEUTICS Hedge Fund Activity
We have seen 218 institutional investors add shares of SAREPTA THERAPEUTICS stock to their portfolio, and 262 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 1,285,118 shares (-11.5%) from their portfolio in Q1 2025, for an estimated $82,016,230
- MORGAN STANLEY added 980,467 shares (+98.9%) to their portfolio in Q1 2025, for an estimated $62,573,403
- JANUS HENDERSON GROUP PLC removed 963,478 shares (-22.3%) from their portfolio in Q1 2025, for an estimated $61,489,165
- ORBIMED ADVISORS LLC removed 963,400 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $61,484,188
- DEEP TRACK CAPITAL, LP added 899,731 shares (+inf%) to their portfolio in Q1 2025, for an estimated $57,420,832
- Y-INTERCEPT (HONG KONG) LTD added 822,799 shares (+1736.5%) to their portfolio in Q2 2025, for an estimated $14,069,862
- ABERDEEN GROUP PLC added 592,125 shares (+91.1%) to their portfolio in Q2 2025, for an estimated $10,125,337
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SAREPTA THERAPEUTICS Congressional Stock Trading
Members of Congress have traded $SRPT stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SRPT stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 04/14.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
SAREPTA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $SRPT in the last several months. We have seen 7 firms issue buy ratings on the stock, and 4 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 07/29/2025
- Needham issued a "Underperform" rating on 07/29/2025
- Wells Fargo issued a "Overweight" rating on 07/24/2025
- Jefferies issued a "Buy" rating on 07/24/2025
- Citigroup issued a "Sell" rating on 07/24/2025
- B of A Securities issued a "Underperform" rating on 07/23/2025
- Baird issued a "Outperform" rating on 07/17/2025
To track analyst ratings and price targets for SAREPTA THERAPEUTICS, check out Quiver Quantitative's $SRPT forecast page.
SAREPTA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $SRPT recently. We have seen 24 analysts offer price targets for $SRPT in the last 6 months, with a median target of $24.5.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $22.0 on 07/30/2025
- Kostas Biliouris from BMO Capital set a target price of $50.0 on 07/29/2025
- Anupam Rama from JP Morgan set a target price of $24.0 on 07/29/2025
- Biren Amin from Piper Sandler set a target price of $15.0 on 07/29/2025
- William Pickering from Bernstein set a target price of $13.0 on 07/29/2025
- Hartaj Singh from Oppenheimer set a target price of $37.0 on 07/29/2025
- Matthew Harrison from Morgan Stanley set a target price of $20.0 on 07/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
